AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10680804 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of early CT signs
Number of subjects: 514
Study 10680804 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoaraiosis or previous lacunar infarcts
Number of subjects: 514
Study 10680804 — intervention group
Group type: EXPERIMENTAL
Intervention: PMH/SMS plus leukoaraiosis or previous lacunes
Number of subjects: 514
Study 9424969 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-gauge Quincke cannula
Number of subjects: 481
Study 9424969 — intervention group
Group type: COMPARATOR
Intervention: 27-gauge Quincke cannula
Number of subjects: 481
Study 9424969 — intervention group
Group type: COMPARATOR
Intervention: 26-gauge Atraucan cannula
Number of subjects: 481
Study 9424969 — intervention group
Group type: COMPARATOR
Intervention: 27-gauge Whitacre cannula
Number of subjects: 481
Study 9424969 — intervention group
Group type: EXPERIMENTAL
Intervention: Recumbency (bed rest for 24 hours)
Number of subjects: 481
Study 9424969 — intervention group
Group type: COMPARATOR
Intervention: Early ambulation (getting up as early as possible)
Number of subjects: 481
Study 9424969 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 481
Study 8382919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (2500 IU)
Number of subjects: 194
Study 8382919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium (3075 IU)
Number of subjects: 194
Study 8382919 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 194
Study 30699415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enarodustat 2 mg, 4 mg, or 6 mg once daily for 6 weeks (Period 1) followed by 24 weeks of open enarodustat treatment (Period 2)
Number of subjects: 0
Study 30699415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enarodustat (various doses)
Number of subjects: 0
Study 30699415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30699415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enarodustat
Number of subjects: 0
Study 28185996 — intervention group
Group type: EXPERIMENTAL
Intervention: Shade sails in passive recreation areas (PRAs)
Number of subjects: 145
Study 28185996 — intervention group
Group type: COMPARATOR
Intervention: Unshaded PRAs
Number of subjects: 145
Study 28185996 — intervention group
Group type: EXPERIMENTAL
Intervention: Shade sails in PRAs
Number of subjects: 145
Study 26805494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity, nutritional education, telephone call counseling, health counseling, monitoring for lifestyle, affective support) for six weeks
Number of subjects: 49
Study 24093847 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial blush grade 2/3
Number of subjects: 2367
Study 24093847 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment resolution ≥50%
Number of subjects: 2367
Study 24093847 — intervention group
Group type: COMPARATOR
Intervention: Myocardial blush grade 0/1
Number of subjects: 2367
Study 21394123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 0
Study 21394123 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass Ionomer Cement
Number of subjects: 0
Study 21394123 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin Composite
Number of subjects: 0
Study 21394123 — intervention group
Group type: COMPARATOR
Intervention: Negative Control Group
Number of subjects: 0
Study 18491405 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 19
Study 18491405 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term statin use
Number of subjects: 19
Study 16829768 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy after 16 hours (group A)
Number of subjects: 682
Study 16829768 — intervention group
Group type: COMPARATOR
Intervention: Lymphoscintigraphy after 2.5 hours (group B)
Number of subjects: 682
Study 15452046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide
Number of subjects: 33
Study 11302591 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal testing machine (in vitro)
Number of subjects: 8
Study 11302591 — intervention group
Group type: EXPERIMENTAL
Intervention: Debonding device (in vitro)
Number of subjects: 8
Study 11302591 — intervention group
Group type: EXPERIMENTAL
Intervention: Debonding device (in vivo)
Number of subjects: 8
Study 11302591 — intervention group
Group type: COMPARATOR
Intervention: Control group (in vitro)
Number of subjects: 8
Study 9069477 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple system atrophy with vocal cord palsy
Number of subjects: 12
Study 9069477 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple system atrophy without vocal cord palsy
Number of subjects: 12
Study 9069477 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 12
Study 9069477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MSA groups
Number of subjects: 12
Study 9069477 — intervention group
Group type: EXPERIMENTAL
Intervention: MSA with vocal cord palsy
Number of subjects: 12
Study 9069477 — intervention group
Group type: EXPERIMENTAL
Intervention: MSA without vocal cord palsy
Number of subjects: 12
Study 8441107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline therapy
Number of subjects: 29
Study 8441107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose in water)
Number of subjects: 29
Study 3535158 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (high-dose)
Number of subjects: 120
Study 3535158 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (low-dose)
Number of subjects: 120
Study 3535158 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-Dihydroergotamine (heparin-DHE)
Number of subjects: 120
Study 3535158 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 30032466 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal anterolateral (TFA) approach
Number of subjects: 104
Study 30032466 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal posterolateral (TFP) approach
Number of subjects: 104
Study 30032466 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfacet indirect (TFT) approach
Number of subjects: 104
Study 26932797 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication regimen (pantoprazole 40 mg b.i.d., bismuth subcitrate 120 mg q.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d. for 14 days)
Number of subjects: 80
Study 24808113 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed list only
Number of subjects: 440
Study 24808113 — intervention group
Group type: EXPERIMENTAL
Intervention: Open‐ended question only
Number of subjects: 440
Study 24808113 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (printed list + open‐ended question)
Number of subjects: 440
Study 24808113 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 440
Study 22313644 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) gel
Number of subjects: 100
Study 22313644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHX gel)
Number of subjects: 100
Study 19581281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment strategy with methotrexate (MTX)
Number of subjects: 0
Study 19581281 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment strategy with methotrexate (MTX)
Number of subjects: 0
Study 18794104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous IL-2 (18 x 10(6) IU/m(2)/d) + s.c. IFN-alpha (6 x 10(6) IU 3 days/week)
Number of subjects: 155
Study 18794104 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous IL-2 (9 x 10(6) or 18 x 10(6) IU) + s.c. IFN-alpha (6 x 10(6) IU 3 days/week)
Number of subjects: 155
Study 18794104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous IL-2
Number of subjects: 155
Study 18794104 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous IL-2
Number of subjects: 155
Study 15945310 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-bonded fixed partial dentures (FPDs)
Number of subjects: 20
Study 15945310 — intervention group
Group type: COMPARATOR
Intervention: Conventional three-unit FPDs (metal-ceramic crowns or complete cast-metal crowns)
Number of subjects: 20
Study 15071264 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD-R pacing
Number of subjects: 0
Study 15071264 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration of chronotropic competence by pacing
Number of subjects: 0
Study 15071264 — intervention group
Group type: COMPARATOR
Intervention: VVI-R pacing
Number of subjects: 0
Study 15071264 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 0
Study 10475719 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg orally) after TYR-free amino acid mixture
Number of subjects: 15
Study 10475719 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine (20 mg orally) after nutritionally balanced amino acid mixture
Number of subjects: 15
Study 8911291 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/d)
Number of subjects: 613
Study 8911291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 1990902 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/morphine anesthesia
Number of subjects: 32
Study 1990902 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane 0.8%
Number of subjects: 32
Study 1990902 — intervention group
Group type: EXPERIMENTAL
Intervention: enflurane 1.7%
Number of subjects: 32
Study 1990902 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane 1.4%
Number of subjects: 32
Study 6355051 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acyclovir
Number of subjects: 0
Study 31764675 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30206194 — intervention group
Group type: EXPERIMENTAL
Intervention: Group REBT program (8 sessions, 180 minutes each, once a week)
Number of subjects: 47
Study 26704170 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (ACTH, oral corticosteroids, vigabatrin)
Number of subjects: 230
Study 26704170 — intervention group
Group type: COMPARATOR
Intervention: Nonstandard therapy
Number of subjects: 230
Study 26704170 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 230
Study 26704170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 230
Study 26704170 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 230
Study 26704170 — intervention group
Group type: EXPERIMENTAL
Intervention: Other nonstandard therapies
Number of subjects: 230
Study 25182696 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to a biologic drug based on NICE guidelines
Number of subjects: 317
Study 25182696 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's choice for switching biologic drugs
Number of subjects: 317
Study 25182696 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of a biologic drug due to lack of effect
Number of subjects: 317
Study 25182696 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Methotrexate in switches to Rituximab
Number of subjects: 317
Study 25182696 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance with NICE guidance
Number of subjects: 317
Study 25182696 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from anti-TNFα to anti-TNFα for inefficacy
Number of subjects: 317
Study 22322086 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 6198
Study 22322086 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 6198
Study 22322086 — intervention group
Group type: COMPARATOR
Intervention: Stress test results
Number of subjects: 6198
Study 20884411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 220
Study 17825729 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE Healthy Lifestyles TEEN program (15-session cognitive-behavioral skills building program including physical activity)
Number of subjects: 23
Study 17825729 — intervention group
Group type: COMPARATOR
Intervention: Attention control program (for the control group)
Number of subjects: 23
Study 15610695 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 0
Study 15610695 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Number of subjects: 0
Study 15610695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0
Study 15610695 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agents targeting vascular endothelial growth factor
Number of subjects: 0
Study 12585186 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI)
Number of subjects: 35
Study 10897293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut versions of films
Number of subjects: 0
Study 10897293 — intervention group
Group type: COMPARATOR
Intervention: Uncut versions of films
Number of subjects: 0
Study 7587188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lea's Shield with spermicide
Number of subjects: 10
Study 7587188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lea's Shield with non-spermicidal lubricant
Number of subjects: 10
Study 7587188 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive diaphragm with spermicide
Number of subjects: 10
Study 7587188 — intervention group
Group type: COMPARATOR
Intervention: Baseline cycle (no contraceptive barrier)
Number of subjects: 10
Study 1783248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol (20 g)
Number of subjects: 6
Study 1783248 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol (20 g)
Number of subjects: 6
Study 1783248 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomalt (20 g)
Number of subjects: 6
Study 1783248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (20 g)
Number of subjects: 6
Study 1783248 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (10 g)
Number of subjects: 6
Study 7073996 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric monitoring with mobility option
Number of subjects: 200
Study 7073996 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 200
Study 7073996 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric monitoring (staying in bed)
Number of subjects: 200
Study 7073996 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric monitoring
Number of subjects: 200
Study 7073996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulant patients with spontaneous deliveries
Number of subjects: 200
Study 30628875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Lighthouse Parenting Program
Number of subjects: 0
Study 30628875 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27858112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabbagh Universal Spring 2 (SUS 2) fixed functional appliance
Number of subjects: 40
Study 27858112 — intervention group
Group type: COMPARATOR
Intervention: Maxillary premolar extraction
Number of subjects: 40
Study 25028999 — intervention group
Group type: EXPERIMENTAL
Intervention: High weight reduction group (HWR; energy restriction 750 kcal·d)
Number of subjects: 15
Study 25028999 — intervention group
Group type: COMPARATOR
Intervention: Low weight reduction group (LWR; energy restriction 300 kcal·d)
Number of subjects: 15
Study 23617466 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept maps (CMs) used in problem-based learning (PBL) tutorials
Number of subjects: 172
Study 23617466 — intervention group
Group type: COMPARATOR
Intervention: Non-concept maps (non-CM) used in problem-based learning (PBL) tutorials
Number of subjects: 172
Study 22072362 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 22
Study 22072362 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (TPN)
Number of subjects: 22
Study 22072362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EN and TPN
Number of subjects: 22
Study 20467617 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain
Number of subjects: 30
Study 20467617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17562928 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone at a maximum dose of 75 mg/kg in phase 1A
Number of subjects: 93
Study 17562928 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone at 60 mg/kg per day for 1 month in phase 1B
Number of subjects: 93
Study 15155308 — intervention group
Group type: EXPERIMENTAL
Intervention: IV KET (9 microg. kg(‐1). min(‐1); 45 min)
Number of subjects: 11
Study 15155308 — intervention group
Group type: EXPERIMENTAL
Intervention: IV KET (9 microg. kg(‐1). min(‐1); 45 min) plus MO (10 microg. kg(‐1). min(‐1); 10 min)
Number of subjects: 11
Study 15155308 — intervention group
Group type: COMPARATOR
Intervention: MO (10 microg. kg(‐1). min(‐1); 10 min)
Number of subjects: 11
Study 15155308 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline; 10 min)
Number of subjects: 11
Study 11202757 — intervention group
Group type: EXPERIMENTAL
Intervention: VSQLQ administered via personal interview
Number of subjects: 304
Study 9222910 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel decompression
Number of subjects: 100
Study 9222910 — intervention group
Group type: EXPERIMENTAL
Intervention: Open carpal tunnel decompression
Number of subjects: 100
Study 9222910 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals (control group)
Number of subjects: 100
Study 1542838 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with morphine sulfate
Number of subjects: 55
Study 1542838 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) morphine sulfate
Number of subjects: 55
Study 3933984 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (10 mg, once daily)
Number of subjects: 15
Study 3933984 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (10 mg, once daily)
Number of subjects: 15
Study 3933984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31097971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tian Jiu (TJ) therapy
Number of subjects: 138
Study 31097971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 31097971 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 138
Study 30571753 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training group (n = 76)
Number of subjects: 151
Study 30571753 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training group (n = 75)
Number of subjects: 151
Study 30571753 — intervention group
Group type: COMPARATOR
Intervention: Comparison between strength and balance groups
Number of subjects: 151
Study 26708025 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation education session
Number of subjects: 30
Study 26708025 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 25240556 — intervention group
Group type: EXPERIMENTAL
Intervention: Wool cap (90 min)
Number of subjects: 18
Study 25240556 — intervention group
Group type: COMPARATOR
Intervention: No wool cap (90 min)
Number of subjects: 18
Study 25240556 — intervention group
Group type: EXPERIMENTAL
Intervention: Wool cap
Number of subjects: 18
Study 25240556 — intervention group
Group type: COMPARATOR
Intervention: No wool cap
Number of subjects: 18
Study 22692351 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field (IF) radiotherapy, total of 30 Gy
Number of subjects: 3710
Study 20819551 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-site phacotrabeculectomy
Number of subjects: 2
Study 18670229 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective HLA-B*5701 screening
Number of subjects: 0
Study 17140502 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPHA form
Number of subjects: 227
Study 17140502 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 227
Study 15600133 — intervention group
Group type: EXPERIMENTAL
Intervention: Problems writing group
Number of subjects: 42
Study 15600133 — intervention group
Group type: COMPARATOR
Intervention: Hobbies writing group
Number of subjects: 42
Study 15600133 — intervention group
Group type: COMPARATOR
Intervention: No writing group
Number of subjects: 42
Study 10663912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotablation
Number of subjects: 0
Study 10663912 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 0
Study 8781764 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide (6 pmol.kg‐1.min‐1)
Number of subjects: 12
Study 8781764 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 12
Study 1345049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg bid for 7 days)
Number of subjects: 12
Study 1345049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7437259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heroin (diamorphine) 2.5 mg and 5 mg for non-dependent; 1/6, 1/3, and 1/2 of prescribed daily dose for dependent subjects
Number of subjects: 0
Study 7437259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31714798 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Community Psychiatric Treatment (ICPT)
Number of subjects: 13
Study 31436621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurix hematogel
Number of subjects: 129
Study 31436621 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary care
Number of subjects: 129
Study 28800895 — intervention group
Group type: EXPERIMENTAL
Intervention: WeCareAdvisor™ (immediate treatment group)
Number of subjects: 57
Study 28800895 — intervention group
Group type: COMPARATOR
Intervention: WeCareAdvisor™ (delayed treatment group)
Number of subjects: 57
Study 26347052 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training with rhythmical cues (BRT)
Number of subjects: 150
Study 26347052 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training (MT) without rhythmical auditory cues
Number of subjects: 150
Study 26347052 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 150